Skip to content

Instant Intelligence for Biotech Investors

Home
Tools
Alerts
About
Join ScanScor
Log In
- Panel

ScanScor

Biotech Stock Alerts and Breakout Prediction

ScanScor

Biotech Stock Alerts and Breakout Prediction

Predictions
Scores
News Stream

speculative

AI Biomed Predictions

CYCC – Critical Clinical Trials Approach for Cyclacel Amid Financial Turmoil

ScanScor Admin / July 4, 2025

← Previous 1 2

Search

Tools

Predictions
Scores
News Stream

Recent Comments

Recent Comments

1 month ago KRRO – Korro’s next AATD no... – Catalyst REALIZED, price thesis weakly realized or not re... by ScanScor Admin
1 month ago CRDF – ASCO Data Could Deci... – BROKEN is defensible, but I would make it a specific kind... by ScanScor Admin
1 month ago GTBP – GTB-5550 clinical la... – GTBP — Does not qualify for a new prediction today. Reas... by ScanScor Admin
1 month ago CRDF – ASCO Data Could Deci... – Our NDAPR parser choked on the response that included a p... by ScanScor Admin
1 month ago LXRX – Lexicon Gears Up for... – Original thesis: BROKEN Reason: It was built around ... by ScanScor Admin

Recent Posts

CRBP – Corbus Faces Its Next Real Repricing on TEMPO-1 Launch
MNPR – Mid-2026 NDA filing could reignite Monopar’s rare-disease rally
ATYR – June IND reset could spark aTyr’s post-failure rebound
ZNTL – ASCO follow-through could spark Zentalis’ next ovarian cancer rerating
UNCY – UNCY Faces Make-or-Break FDA Catalyst With Approval Upside

ScanScor empowers traders and investors with instant
AI-driven access to trusted intelligence.

🧠 Powered by real-time AI
🔍 Trained to find the moment before it moves

Terms and Conditions
About
Join the ScanScor Revolution

Disclaimer: ScanScor provides research and educational information only. Nothing on this site is financial advice or a recommendation to buy or sell securities. ScanScor does not provide forecasts or guarantee any outcomes. Past performance is not indicative of future results.

Copyright © 2026 ScanScor

Best viewed on desktop. Mobile optimization coming soon.

Scroll to Top